Champions Oncology and Teva sign a discovery and drug development partnership

Champions Oncology announced the signing of a new discovery and drug development partnership with Teva Pharmaceutical Industries which will utilize Champions TumorGraft technology platform to enhance and accelerate the clinical development of several of Teva's oncology compounds.Under the terms of the agreement, Teva will pay Champions an upfront fee and Champions may also receive milestone payments and royalties for the compounds being studied if the response hypotheses are successfully utilized for clinical trial design and resulting commercial success of the compounds.

View Comments (0)